---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-25-000063"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T16:53:17.541256+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Allogene Q1 net loss $59.7M; ALPHA3 milestone delayed to 1H 2026; cash runway to 2H 2027

## Summary
- Net loss $59.7M ($0.28/sh); R&D $50.2M, G&A $15M; cash, equivalents & investments $335.5M.
- ALPHA3 (cema-cel) lymphodepletion/futility analysis shifted to 1H 2026; >250 patients consented, ~50 sites activated.
- ALLO-329 RESOLUTION basket trial in AID starts mid-2025; proof-of-concept data moved to 1H 2026.
- ALLO-316 TRAVERSE updated Phase 1b results to be presented at ASCO June 1, 2025.
- Cash runway extended into 2H 2027; 2025 guidance: cash burn ~$150M, GAAP op ex ~$230M.

## SEC filing metadata
- accession: 0001737287-25-000063
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728725000063/0001737287-25-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728725000063/allo-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-25-000063
- JSON: https://secwatch.observer/filing/0001737287-25-000063.json
- Plain text: https://secwatch.observer/filing/0001737287-25-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.